^
Association details:
| Biomarker: | AR splice variant 7 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Thus AR-V7 may be a useful predictive biomarker in men with metastatic CRPC after progression on abiraterone or enzalutamide. These clinical experiences suggest that AR-V7 assays are promising predictors of abiraterone and enzalutamide resistance.
Source:
Title:
A Preliminary Study on the Prediction of Outcomes of Patients with Castration-Resistant Prostate Cancer Treated by Abiraterone Using AR-FL and AR-V7 Transcript Levels in Peripheral Blood and Serum Levels of Neuroendocrine Tumor Markers
Excerpt:
...Transcript levels of AR-FL and AR-V7 - Transcript levels of AR-FL and AR-V7; the level of neuron-specific enolase - the level of neuron-specific enolase; the level of pro-gastrin-releasing peptide - the level of pro-gastrin-releasing peptide...
Trial ID:
Source:
Title:
Is monitoring of plasmalevels of abiraterone a possible predictor for the response to Abiraterone treatment, in patients with metastatic prostate cancer? Is de bloedconcentratie van abirateron van voorspellende waarde voor het effect van dit geneesmiddel in patiënten met uitgezaaid prostaatkanker?
Excerpt:
...-To explore the relation between novel early and easily assessable biomarkers (PSA-mRNA, PCA3-mRNA, TMPRSS2:ERP gene fusion-mRNA, (currently under development)ARv7 mRNA and ARwt mRNA) and treatment response after 3 months and 6 months of therapy -To explore whether the degree of reductions of these novel biomarkers are related to abiraterone exposure (AUC) after 3 and 6 months of therapy -To explore the relation between traditional PD biomarkers (serum PSA, DHEA, LDH, AP) and treatment response after 3 and 6 months of therapy -To explore whether the degree of reductions in PSA, DHEA, LDH, AP are related to abiraterone exposure (AUC) after 3 and 6 months of therapy...
Trial ID:
More C2 evidence
Source:
Title:
Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®) Korrelation zwischen gebräuchlichen klinischen Ergebnis-Parametern (rPFS, OS), CTC-Änderungen und AR-V7-Status (Androgenrezeptor-Splice-Variante 7) bei Patienten mit mCRPC unter Erstlinientherapie mit Abirateron (Zytiga®)
Excerpt:
...Radiologic progression-free survival under tehrapy with Zytiga® as first lien therapy with consideration of the AR-V7-status and the number of CTCs. ...
Trial ID:
Source:
Title:
CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION
Excerpt:
...Comparison predictive value of miRNA and ARV7 status in treatment efficacy`Toxicity (CTCAE v.4.03 scale)...
Trial ID:
Less C2 evidence
Source:
Title:
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Published date:
03/14/2019
Excerpt:
...Androgen receptor splice variant 7 (AR-V7)...We enrolled 118 men with mCRPC who were starting abiraterone or enzalutamide treatment. Detection of AR-V7 in CTCs by two blood-based assays is independently associated with shorter PFS and OS with abiraterone or enzalutamide…
DOI:
10.1200/JCO.18.01731
Trial ID:
Source:
Title:
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
Excerpt:
Detection of AR-V7 in circulating tumor cells from patients with castration-resistant prostate cancer may be associated with resistance to enzalutamide and abiraterone.
DOI:
10.1056/NEJMoa1315815
